Opendata, web and dolomites

NanoSil4Cancer

Smart Multifunctional silica-based Nanoparticles for Targeted Therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NanoSil4Cancer project word cloud

Explore the words cloud of the NanoSil4Cancer project. It provides you a very rough idea of what is the project "NanoSil4Cancer" about.

drugs    adherence    13511    molecules    search    dramatically    smart    feasibility    thomson    nevertheless    interests    individuate    released    pharma    optimized    technologies    therapy    pro    stakeholder    formulated    epo    minimizing    290b    silica    big    nanosil4cancer    environmental    communication    90    final    acid    patent    strategical    toxicity    fr    release    chemotherapy    limited    active    nanoparticles    commercial    sectorial    attractiveness    mesoporous    therapeutic    vehicles    customer    platform    accelerate    acquire    proprietary    saving    cells    sme    bortezomib    compartments    internalized    prototype    trend    pct    cancer    receptor    healthcare    intracellular    antitumor    buy    missing    lowering    folic    prototypes    agents    sensitive    market    medical    device    drug    depends    nano    folate    competence    report    ph    efficacy    marketing    minimize    customers    ep06745236    nanotechnologies    sparing    innovative    normal    overexpressing    dosage    business    patients   

Project "NanoSil4Cancer" data sheet

The following table provides information about the project.

Coordinator
NANOSILICAL DEVICES SRL 

Organization address
address: VIA PIETRO BUCCI CUBO 44A
city: RENDE
postcode: 87036
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.nanosilicaldevices.com/it/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-09-01   to  2017-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NANOSILICAL DEVICES SRL IT (RENDE) coordinator 50˙000.00

Map

 Project objective

NanoSil4Cancer project will be able to accelerate the uptake of nanotechnologies, by developing, mesoporous silica-based prototypes of nano-vehicles, according to an innovative and proprietary approach (EP06745236), active in smart chemotherapy. This is aimed to minimize toxicity and the side effects of the traditional antitumor agents and to increase their therapeutic potential. This technology platform enables customers’ molecules to be formulated as pH–sensitive pro-drugs and introduced in smart nanoparticles able to reach the intracellular compartments of cancer cells where the drug is released. Development of new prototypes will lead to new patent applications. Recently we have developed and optimized a device, provided with folic acid, able to manage bortezomib release in cancer cells overexpressing folate receptor, FR (PCT-13511). The nanoparticles are only recognized and internalized by FR overexpressing cancer cells, where they release the drug, sparing normal cells. Nevertheless, our technology is general, not limited to a specific prototype, but depends on customer's needs, market and final users' needs. The feasibility study will individuate strategical market interests to address the prototypes production as business opportunities for our SME. Market trend and the role of Big Pharma will be defined to identify commercial partners and stakeholder to be involved in the project. We will buy sectorial report, we will use patent search such as EPO and Thomson, we will acquire missing competence in marketing and communication. The approach will represent a strong step forward in chemotherapy, improving the efficacy, lowering drug dosage (thus minimizing side effects for cancer patients and environmental impact), other than dramatically lowering EU Healthcare costs (up to 80-90% saving on non-adherence to the therapy costs, estimated in $290B/year), allowing Europe to increase its attractiveness in the field of innovative medical technologies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NANOSIL4CANCER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NANOSIL4CANCER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More